

CANCER GENE THERAPY

Past Achievements and Future Challenges

ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY

Editorial Board:

NATHAN BACK, *State University of New York at Buffalo*

IRUN R. COHEN, *The Weizmann Institute of Science*

DAVID KRITCHEVSKY, *Wistar Institute*

ABEL LAJTHA, *N. S. Kline Institute for Psychiatric Research*

RODOLFO PAOLETTI, *University of Milan*

Recent Volumes in this Series

- Volume 465
CANCER GENE THERAPY: Past Achievements and Future Challenges
Edited by Nagy A. Habib
- Volume 466
CURRENT VIEWS OF FATTY ACID OXIDATION AND KETOGENESIS:
From Organelles to Point Mutations
Edited by Patti A. Quant and Simon Eaton
- Volume 467
TRYPTOPHAN, SEROTONIN, AND MELATONIN: Basic Aspects and Applications
Edited by Gerald Huether, Walter Kochen, Thomas J. Simat, and Hans Steinhart
- Volume 468
THE FUNCTIONAL ROLES OF GLIAL CELLS IN HEALTH AND DISEASE:
Dialogue between Glia and Neurons
Edited by Rebecca Matsas and Marco Tsacopoulos
- Volume 469
EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION,
AND RADIATION INJURY, 4
Edited by Kenneth V. Honn, Lawrence J. Marnett, and Santosh Nigam
- Volume 470
COLON CANCER PREVENTION:
Dietary Modulation of Cellular and Molecular Mechanisms
Edited under the Auspices of the American Institute for Cancer Research
- Volume 471
OXYGEN TRANSPORT TO TISSUE XXI
Edited by Andras Eke and David T. Delpy
- Volume 472
ADVANCES IN NUTRITION AND CANCER 2
Edited by Vincenzo Zappia, Fulvio Delia Ragione, Alfonso Barbarisi,
Gian Luigi Russo, and Rossano Dello Iacovo
- Volume 473
MECHANISMS IN THE PATHOGENESIS OF ENTERIC DISEASES 2
Edited by Prem S. Paul and David H. Francis
- Volume 474
HYPOXIA: INTO THE NEXT MILLENNIUM
Edited by Robert C. Roach, Peter D. Wagner, and Peter H. Hackett

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

CANCER GENE THERAPY

Past Achievements and Future Challenges

Edited by

Nagy A. Habib

*Imperial College School of Medicine
Hammersmith Hospital
London, United Kingdom*

KLUWER ACADEMIC PUBLISHERS
NEW YORK, BOSTON, DORDRECHT, LONDON, MOSCOW

eBook ISBN: 0-306-46817-4
Print ISBN: 0-306-46191-9

©2002 Kluwer Academic Publishers
New York, Boston, Dordrecht, London, Moscow

Print ©2000 Kluwer Academic Publishers
New York

All rights reserved

No part of this eBook may be reproduced or transmitted in any form or by any means, electronic, mechanical, recording, or otherwise, without written consent from the Publisher

Created in the United States of America

Visit Kluwer Online at: <http://kluweronline.com>
and Kluwer's eBookstore at: <http://ebooks.kluweronline.com>

To all the clinicians, scientists, and various other people who are passionate about cancer research and have dedicated their lives to the advancement of knowledge and the discovery of a cancer cure

PREFACE

With the coming of the new millennium we are witnessing a revolution in our understanding of cancer genetics. These are very exciting times. Today we have at our disposal the technology to diagnose abnormalities in our cancer genes and the means to correct the deficit and very soon we will have the complete sequence of the human genome.

With the use of gene chip technology the way doctors will be able to assess patients will change completely. Today we can diagnose abnormalities in ten thousand genes and within a short period of time we will be able to screen through our genome and discover potential abnormalities in our proto-oncogenes, tumour suppressor genes, differentiating genes, apoptotic genes and pro-inflammatory genes. In this book various authors have highlighted specific genes that could be expressed, overexpressed, neutralised or harnessed to achieve cancer control.

The problem of transferring the therapeutic gene into the cancer cell has been partly addressed with major developments in the field of naked plasmid DNA, adenovirus, retrovirus and adeno-associated viruses. However, further improvements are yet to be made to achieve significant gene transfer. Gene expression, in particular specificity of gene transfer, is obviously an important issue and one which is highlighted in this book by the use of specific promoter.

There are many potentially promising avenues to pursue to achieve cancer cell apoptosis or necrosis and some pre-clinical and clinical data are promising. Various clinical studies, including the use of Ad p53 and Ad E1B deleted, are progressing from phase II into phase III studies and are showing promise when their use is combined with chemotherapy.

Although progress in this field has been relatively slow, gene therapy has come of age. Already the first gene therapy drug has FDA approval for use in patients with CMV retinitis to save eyesight. Cancer is a more problematic disorder to solve as it involves many overexpressed oncogenes and several deleted or mutated tumour suppressor genes. Although cure is unlikely to happen tomorrow, cancer gene therapy is undoubtedly here to stay.

ACKNOWLEDGMENTS

I would like to acknowledge Sandra Doherty for putting this book together and for charming various authors for their manuscripts.

CONTENTS

I. The Clinical Problem

1. Management Problems in Oncology 3
Susan J. Cleator and Pat Price

II. Vectors

2. Adenoviral Vectors 13
Prem Seth

3. Retrovirus Vectors 23
Yasuhiro Takeuchi and Massimo Pizzato

4. Targetable Gene Delivery Vectors 37
Paul L. Hallenbeck and Susan C. Stevenson

5. Human α -fetoprotein Transcriptional Regulatory Sequences:
Application to Gene Therapy..... 47
Taiki Tamaoki

6. Tumor-Targeted *Salmonella*: Highly Selective Delivery Vectors 57
David Bermudes, Brooks Low, and John Pawelek

7. Mutant Adenoviruses Selectively Replication-Competent in Tumor Cells ... 65
Makoto Sunamura

8. Polyoma and Papilloma Virus Vectors for Cancer Gene Therapy..... 73
Nina Krauzewicz and Beverly E. Griffin

9. Cochleates: Lipid-Based Vehicles for Gene Delivery—Concept,
Achievements and Future Development 83
Leila Zarif and Raphael J. Mannino

10. The Use of Skeletal Muscle to Express Genes for the Treatment of
Cancer 95
Stephen Coe, Michael Harron, Marc Winslet, and Geoffrey Goldspink

III. Cell Cycle Control

11. Adhesion Molecules in Cancer Biology.....	115
Yaw Ohene-Abuakwa and Massimo Pignatelli	
12. Cell Cycle Control	127
Vivien J. Tannoch, Phil W. Hinds and Li-Huei Tsai	

IV. Apoptosis

13. Killer/DR5, A Novel DNA-Damage Inducible Death Receptor Gene, Links the p53-Tumor Suppressor to Caspase Activation and Apoptotic Death	143
Gen Sheng Wu, Kunghong Kim, and Wafik S. El-Deiry	
14. Apoptin®	153
Alexandra Pietersen and Mathieu H. M. Noteborn	
15. Adenovirus-Mediated Herpes Simplex Thymidine Kinase Gene Therapy For Brain Tumors.....	163
Anu-Maaria Sandmair, Matti Vapalahti, and Seppo Ylä-Herttuala	
16. Development of Clinical Trial of E1A Gene Therapy Targeting HER-2/ <i>neu</i> -overexpressing Breast and Ovarian Cancer	171
M-C. Hung, G. N. Hortobagyi, and N. T. Ueno	

V. Tumour Suppressor Genes

17. Pre-clinical Studies with Tumor Suppressor Genes	183
Prem Seth	
18. Gene Therapy for Liver Tumors	193
Ragai R. Mitry, Marc R. Mansour, Roman Havlík, and Nagy A. Habib	
19. Adenovirus-mediated Transfer of a p53 Gene in Ovarian Cancer.....	207
Junzo Kigawa and Naoki Terakawa	

VI. Other Systems

20. Eliciting Hyperacute Rejection as a Tumor Killing Strategy: Herpes Amplicon Vector Transfer of the $\alpha(1,3)$ Galactosyltransferase Gene ...	217
Charles J. Link Jr., Daniel J. Hellrung, Tatiana Seregina, and Suming Wang	

21. Innate Immune Therapy for Cancer: Screen for Molecules molecules of Activating the Innate Immune System	229
Tsukasa Seya, Nasim A. Begum, Midori Nomura, Shoutaro Tsuji, Misako Matsumoto, Akira Hayashi, Ichiro Azuma, and Kumow Toyoshima	
22. <i>Mda-7</i> : A Novel Melanoma Differentiation Associated Gene with Promise for Cancer Gene Therapy	239
Malavi T. Madireddi, Zao-Zhong Su, Charles S. H. Young, Neil I. Goldstein, and Paul B. Fisher	

VII. Antisense and Ribozymes

23. Antisense IGF and Antisense IGF-IR Therapy of Malignancy	265
Hao Wang, Yanjun Liu, Lixin Wei, and Yajun Guo	
24. Sensitization of Tumors to Chemotherapy Through Gene Therapy	273
Ruth A. Gjerset and Dan Mercola	
25. Design and Testing of Ribozymes for Cancer Gene Therapy	293
James S. Norris, Brian Hoel, Dale Voeks, Frideriki Maggouta, Michael Dahm, Weihua Pan, and Gary Clawson	
26. Ribozymes: Their Design and Use in Cancer	303
Philip C. Turner	
27. The Approach of Triple Helix Formation in Control of Gene Expression and the Treatment of Tumors Expressing IGF-1	319
Lia C. Upegui-Gonzalez, Jean-Christophe François, Adama Ly, and Jerzy Trojan	

VIII. Immuno-Modulation

28. Dendritic Cell-based Immunization for Cancer Therapy	335
Michael A. Morse and H. Kim Lyerly	
29. Hybrid Cell Vaccination for Cancer Immunotherapy	347
Peter Walden	
30. Modulation of the Immune Response Through 4-1BB	355
Gabriel Sica and Lieping Chen	
31. Heat Shock Proteins in Cancer Therapy	363
Katalin V. Lukacs, Olivier E. Pardo, M. Jo Colston, Duncan M. Geddes, and Eric WFW Alton	

32. Bi-Specific Antibodies in Cancer Therapy	369
Hao Wang, Yanjun Liu, Lixin Wei, and Yajun Guo	
33. B7.1 and Cytokines: Synergy in Cancer Gene Therapy	381
Marcel Kuiper, Raquel Sanches, Yves-Jean Bignon, and Farzin Farzaneh	
34. Intralesional Vaccinia/GM-CSF Recombinant Virus in the Treatment of Metastatic Melanoma.....	391
Michael J. Mastrangelo, Henry C. Maguire Jr., Edmund C. Lattime	

IX. Suicidal Genes

35. Approaches to Gene-Directed Enzyme Prodrug Therapy (GDEPT).....	403
Caroline J. Springer and Ion Niculescu-Duvaz	
36. Suicide Gene Therapy	411
Scott M. Freeman	
37. Adenoviruses as Gene Delivery Vectors	423
Anu-Maaria Sandmair, Matti Vapalahti, and Seppo Ylä-Herttuala	

X. Angiogenesis Control

38. Evaluation of an Inhibitor of DNA Methylation, 5-aza-2'-deoxycytidine, for the Treatment of Lung Cancer and the Future Role of Gene Therapy	433
Richard L. Momparler, Nicoletta Eliopoulos, and Joseph Ayoub	
39. Vascular Endothelial Growth Factor as a Target for Cancer Gene Therapy	447
Josephine Tuong Nguyen	
40. Adeno-Associated Virus and Other Potential Vectors for Angiostatin and Endostatin Gene Therapy	457
Josephine Tuong Nguyen	

XI. Matrix Metallo Proteinase

41. Potential Applications of Tissue Inhibitor of Metalloproteinase (TIMP) Overexpression for Cancer Gene Therapy	469
Andrew H. Baker, Matti Ahonen, and Veli-Matti Kähäri	
Contributors	485
Index	495